CA2325345A1 - Medicaments for inducing cytotoxic t-cells - Google Patents
Medicaments for inducing cytotoxic t-cells Download PDFInfo
- Publication number
- CA2325345A1 CA2325345A1 CA002325345A CA2325345A CA2325345A1 CA 2325345 A1 CA2325345 A1 CA 2325345A1 CA 002325345 A CA002325345 A CA 002325345A CA 2325345 A CA2325345 A CA 2325345A CA 2325345 A1 CA2325345 A1 CA 2325345A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- amino acid
- compound according
- peptide
- hiv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract 9
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 title claims abstract 4
- 230000001939 inductive effect Effects 0.000 title abstract 2
- 150000001413 amino acids Chemical class 0.000 claims abstract 28
- 229940024606 amino acid Drugs 0.000 claims abstract 21
- 150000001875 compounds Chemical class 0.000 claims abstract 20
- 150000007523 nucleic acids Chemical class 0.000 claims abstract 8
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims abstract 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract 7
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract 7
- 229960000310 isoleucine Drugs 0.000 claims abstract 7
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims abstract 7
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims abstract 6
- 239000004474 valine Substances 0.000 claims abstract 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims abstract 5
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims abstract 5
- 229940009098 aspartate Drugs 0.000 claims abstract 5
- 108020004707 nucleic acids Proteins 0.000 claims abstract 4
- 102000039446 nucleic acids Human genes 0.000 claims abstract 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims abstract 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000004473 Threonine Substances 0.000 claims abstract 2
- 235000001014 amino acid Nutrition 0.000 claims 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims 11
- 241000700605 Viruses Species 0.000 claims 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 6
- 241000725303 Human immunodeficiency virus Species 0.000 claims 5
- 235000018102 proteins Nutrition 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- JTEGQNOMFQHVDC-RQJHMYQMSA-N 4-amino-1-[(2s,5r)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)SC1 JTEGQNOMFQHVDC-RQJHMYQMSA-N 0.000 claims 2
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 claims 2
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 241000700721 Hepatitis B virus Species 0.000 claims 2
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 claims 2
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 claims 2
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 claims 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims 2
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 claims 2
- 229960004748 abacavir Drugs 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 229960001627 lamivudine Drugs 0.000 claims 2
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims 2
- 239000002502 liposome Substances 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108010028921 Lipopeptides Proteins 0.000 claims 1
- 108090001030 Lipoproteins Proteins 0.000 claims 1
- 102000004895 Lipoproteins Human genes 0.000 claims 1
- 108010046117 N-palmitoyl-5,6-dipalmitoyl-S-glycerylcysteinyl-seryl-serine Proteins 0.000 claims 1
- 241000607142 Salmonella Species 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 108010067390 Viral Proteins Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 1
- 229940031348 multivalent vaccine Drugs 0.000 claims 1
- 239000013600 plasmid vector Substances 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- XVQKZSLOGHBCET-INVHGPFASA-N tripalmitoyl-S-glyceryl-cysteinyl-seryl-serine Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O)CSCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC XVQKZSLOGHBCET-INVHGPFASA-N 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Abstract
The invention relates to compounds containing an amino acid with the sequenc e X1-Y-X2-D-D-X3 or a nucleic acid coding this amino acid, X1 being at least o ne chosen amino acid, Y being tyrosine, X2 being an amino acid chosen from the following group: valine, isoleucine and leucine; D being aspartate and X3 being at least one other chosen amino acid, the following amino acids being excluded: TLVLQYVDDLLL and ILVLQYVDDLLL, T being threonine, V being valine, I being isoleucine, L being leucine and Q being glutamine. The invention also relates to medicaments for inducing cytotoxic T-cells, containing this class of compounds.
Claims (29)
1. A compound containing or consisting of an amino acid or nucleic acid encoding said amino acid, wherein said amino acid has the following sequence:
X1-Y-X2-D-D-X3, wherein Xl - at least one of any amino acid Y - tyrosine X2 = one amino acid selected from the following group:
valine, isoleucine, and leucine D = aspartate, and X3 = at least one of any additional amino acid, except for the following amino acid sequences:
LRVEYLDDR, TLVLQYVDDLLL, and ILVLQYVDDLLL, with T = threonine, V = valine, I = isoleucine, L = leucine, Q = glutamine, and R = arginine.
X1-Y-X2-D-D-X3, wherein Xl - at least one of any amino acid Y - tyrosine X2 = one amino acid selected from the following group:
valine, isoleucine, and leucine D = aspartate, and X3 = at least one of any additional amino acid, except for the following amino acid sequences:
LRVEYLDDR, TLVLQYVDDLLL, and ILVLQYVDDLLL, with T = threonine, V = valine, I = isoleucine, L = leucine, Q = glutamine, and R = arginine.
2. A compound according to claim 1, wherein said amino acid sequence consists of nine amino acids.
3. A compound according to any one of the preceding claims, wherein X1 is a sequence consisting of four or five amino acids.
4. A compound according to any one of the preceding claims, wherein X3 is a sequence consisting of one or two additional amino acids.
5. A compound according to any one of the preceding claims, wherein said amino acid sequence is a component of a peptide.
6. A compouna according to any one of the preceding claims, wherein said amino acid sequence is a component of a protein.
7. A compound according to any one of the preceding claims, wherein said peptide or protein is coupled to a lipopeptide or lipoprotein, preferably to tripalmitoyl-S-glycerylcysteinyl-seryl-serine.
8. A compound according to any one of the preceding claims, wherein said peptide or protein is contained within a liposome or ISCOM.
9. A compound according to any one of the preceding claims, wherein said peptide or protein is coupled to a viral protein.
10. A compound according to any one of the preceding claims, wherein said peptide is selected from the following group: HIV virus-like particles, HIV gag-particles, or HBs antigens.
11. A compound according to any one of the preceding claims, wherein said peptide is present as a soluble peptide-HLA
complex, preferably as a HLA-A2 tetramer.
complex, preferably as a HLA-A2 tetramer.
12. A compound according to any one of the preceding claims, wherein said peptide is present as a soluble peptide-HLA
complex bound to a liposome.
complex bound to a liposome.
13. A compound according to any one of the preceding claims, wherein said peptide is a component of an antigen-presenting cell, preferably dendritic cell, macrophage, B cell or CD4+ T cell.
14. A compound according to any one of the preceding claims, wherein said amino acid sequence is selected from among the following amino acid sequences:
IVIYQYVDDL (SEQ ID NO:1), IVICQYVDDL (SEQ ID NO:2), IVIYQYIDDL (SEQ ID NO:3), IVICQYIDDL (SEQ ID NO:4), ITIYQYVDDL (SEQ ID NO:5), ITICQYVDDL (SEQ ID NO:6), ITIYQYIDDL (SEQ ID NO:7), ITICQYIDDL (SEQ ID NO:8), IIIYQYVDDL (SEQ ID NO:9), IIICQYVDDL (SEQ ID NO:10) IIIYQYIDDL (SEQ ID NO:11), IIICQYIDDL (SEQ ID NO:12), MVIYQYVDDL (SEQ ID NO:13), MVICQYVDDL (SEQ ID NO:14), MVIYQYIDDL (SEQ ID NO:15), MVICQYIDDL (SEQ ID NO:16), VIYQYVDDL (SEQ ID NO:17), VICQYVDDL (SEQ ID NO:18), VIYQYIDDL (SEQ ID NO:19), VICQYVDDL (SEQ ID NO:20), LIYQYVDDL (SEQ ID NO:21), LICQYVDDL (SEQ ID NO:22), LIYQYIDDL (SEQ ID NO:23), LICQYIDDL (SEQ ID NO:24), TILQYVDDILL (SEQ ID NO:25), TICQYVDDILL (SEQ ID NO:26), ILQYVDDIL (SEQ ID NO:27), ILQYIDDIL (SEQ ID NO:28), TIVQYVDDILL (SEQ ID NO:29), TIVQYIDDILL (SEQ ID NO:30), IVQYIDDIL (SEQ ID NO:31), IVQYIDDIL (SEQ ID NO:32), ILVQYVDDIL (SEQ ID NO:33), ILVQYIDDIL (SEQ ID NO:34), IIIQYVDDIL (SEQ ID NO:35), IIIQYIDDIL (SEQ ID NO:36), ILIQYVDDIL (SEQ ID NO:37), ILIQYIDDIL (SEQ ID NO:38), VLYQYVDDL (SEQ ID NO:39), VLCQYVDDL (SEQ ID NO:40), VLYQYIDDL (SEQ ID NO:41), VLCQYIDDL (SEQ ID NO:42), where C = cysteine, D = aspartate, I = isoleucine, L =
leucine, M = methionine, and Q = glutamine.
IVIYQYVDDL (SEQ ID NO:1), IVICQYVDDL (SEQ ID NO:2), IVIYQYIDDL (SEQ ID NO:3), IVICQYIDDL (SEQ ID NO:4), ITIYQYVDDL (SEQ ID NO:5), ITICQYVDDL (SEQ ID NO:6), ITIYQYIDDL (SEQ ID NO:7), ITICQYIDDL (SEQ ID NO:8), IIIYQYVDDL (SEQ ID NO:9), IIICQYVDDL (SEQ ID NO:10) IIIYQYIDDL (SEQ ID NO:11), IIICQYIDDL (SEQ ID NO:12), MVIYQYVDDL (SEQ ID NO:13), MVICQYVDDL (SEQ ID NO:14), MVIYQYIDDL (SEQ ID NO:15), MVICQYIDDL (SEQ ID NO:16), VIYQYVDDL (SEQ ID NO:17), VICQYVDDL (SEQ ID NO:18), VIYQYIDDL (SEQ ID NO:19), VICQYVDDL (SEQ ID NO:20), LIYQYVDDL (SEQ ID NO:21), LICQYVDDL (SEQ ID NO:22), LIYQYIDDL (SEQ ID NO:23), LICQYIDDL (SEQ ID NO:24), TILQYVDDILL (SEQ ID NO:25), TICQYVDDILL (SEQ ID NO:26), ILQYVDDIL (SEQ ID NO:27), ILQYIDDIL (SEQ ID NO:28), TIVQYVDDILL (SEQ ID NO:29), TIVQYIDDILL (SEQ ID NO:30), IVQYIDDIL (SEQ ID NO:31), IVQYIDDIL (SEQ ID NO:32), ILVQYVDDIL (SEQ ID NO:33), ILVQYIDDIL (SEQ ID NO:34), IIIQYVDDIL (SEQ ID NO:35), IIIQYIDDIL (SEQ ID NO:36), ILIQYVDDIL (SEQ ID NO:37), ILIQYIDDIL (SEQ ID NO:38), VLYQYVDDL (SEQ ID NO:39), VLCQYVDDL (SEQ ID NO:40), VLYQYIDDL (SEQ ID NO:41), VLCQYIDDL (SEQ ID NO:42), where C = cysteine, D = aspartate, I = isoleucine, L =
leucine, M = methionine, and Q = glutamine.
15. A compound according to any one of the preceding claims, wherein said nucleic acid sequence is a DNA or RNA
sequence.
sequence.
16. A compound according to any one of the preceding claims, wherein said nucleic acid sequence is a component of a plasmid or viral vector, preferably a recombinant vaccinia virus, adenovirus, or retroviral vector.
17. A compound according to any one of the preceding claims, wherein said nucleic acid sequence is a component of a bacterial vector, preferably of a recombinant BCG or salmonella vector.
18. A compound according to any one of the preceding claims, wherein said nucleic acid sequence is a component of an inactivated virus, preferably an inactivated HIV virus.
19. A medicament containing as active ingredient a compound according to any one of the preceding claims.
20. A medicament according to claim 19 in form of a vaccine.
21. A medicament according to claim 20 containing polyvalent vaccines.
22. A medicament according to any one of claims 19 through 21, wherein one or more cytokines are contained as adjuvant.
23. A medicament according to any one of claims 19 through 22, wherein interleukin-2 and/or GM-CSF are contained as adjuvant.
24. A method for the prevention or treatment of infections with viruses, preferably mutated HIV, HIV-l, HIV-2, HTLV-I, and HTLV-II viruses or mutated hepatitis B
viruses or a disease responding to induction of cytotoxic T cells, consisting of administering to patient an effective dose of a medicament comprising a peptide of the following sequence:
X1-Y-X2-D-D-X3, wherein X1 = at least one of any amino acid Y = tyrosine, X2 = one amino acid selected from the following group:
valine (V), isoleucine (I), and leucine (L), D = aspartate, and X3 = at least one additional of any amino acid, or a nucleic acid encoding said peptide.
viruses or a disease responding to induction of cytotoxic T cells, consisting of administering to patient an effective dose of a medicament comprising a peptide of the following sequence:
X1-Y-X2-D-D-X3, wherein X1 = at least one of any amino acid Y = tyrosine, X2 = one amino acid selected from the following group:
valine (V), isoleucine (I), and leucine (L), D = aspartate, and X3 = at least one additional of any amino acid, or a nucleic acid encoding said peptide.
25. A method according to claim 24, wherein said mutant viruses are resistant to reverse transcriptase inhibitors.
26. A method according to claim 24 or 25, wherein said mutant viruses are resistant to (-)-2',3'-dideoxy-3'-thiacytidine [=3TC (lamivudine)] , (-)-(1S,4R) -4- [2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol [abacavir], 2',3'-dideoxyinosine [didanosin], 2',3'-dideoxycytidine [zalcitabin], (-)-2'-deoxy-5-fluoro-3'-thiacytidine [=FTC].
27. A use of the following amino acid sequence:
X1-Y-X2-D-D-X3, wherein X1 = at least one of any amino acid Y = tyrosine (T), X2 = one amino acid selected from the following group:
valine (V), isoleucine (I), and leucine (L), D = aspartate, and X3 = at least one of any additional amino acid, or a nucleic acid encoding said peptide, for the preparation of a medicament for the prevention or treatment of infections with viruses, preferably mutated HIV, HIV-1, HIV-2, HTLV-I, and HTLV-II viruses or mutated hepatitis B viruses or a disease responding to induction of cytotoxic T cells.
X1-Y-X2-D-D-X3, wherein X1 = at least one of any amino acid Y = tyrosine (T), X2 = one amino acid selected from the following group:
valine (V), isoleucine (I), and leucine (L), D = aspartate, and X3 = at least one of any additional amino acid, or a nucleic acid encoding said peptide, for the preparation of a medicament for the prevention or treatment of infections with viruses, preferably mutated HIV, HIV-1, HIV-2, HTLV-I, and HTLV-II viruses or mutated hepatitis B viruses or a disease responding to induction of cytotoxic T cells.
28. A use according to claim 27, wherein said mutant viruses are resistant to reverse transcriptase inhibitors.
29. A use according to claim 27 or claim 28, wherein said mutant viruses are resistant to (-)-2',3'-dideoxy-3'-thiacytidine [=3TC (lamivudine)], (-)-(1S, 4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol (abacavir], 2',3'-dideoxyinosine [didanosin], 2',3'-dideoxycytidine [zalcitabin], (-)-2'-deoxy-5-fluoro-3'-thiacytidine [=FTC].
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19814925.5 | 1998-04-03 | ||
| DE19814925A DE19814925C2 (en) | 1998-04-03 | 1998-04-03 | Medicinal products for induction of cytotoxic T cells |
| PCT/EP1999/002249 WO1999051750A1 (en) | 1998-04-03 | 1999-04-01 | Medicaments for inducing cytotoxic t-cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2325345A1 true CA2325345A1 (en) | 1999-10-14 |
| CA2325345C CA2325345C (en) | 2010-06-29 |
Family
ID=7863458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2325345A Expired - Fee Related CA2325345C (en) | 1998-04-03 | 1999-04-01 | Medicaments for inducing cytotoxic t-cells |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1068331B1 (en) |
| JP (1) | JP2002510496A (en) |
| KR (1) | KR20010042400A (en) |
| AT (1) | ATE346935T1 (en) |
| AU (1) | AU3704299A (en) |
| BR (1) | BR9909389A (en) |
| CA (1) | CA2325345C (en) |
| DE (2) | DE19814925C2 (en) |
| WO (1) | WO1999051750A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7619058B2 (en) | 2004-01-20 | 2009-11-17 | Aichi Prefecture | Epitope/peptide recognized by HLA-A2402-restricted Ep-CAM-specific CTL and use of the same |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7731971B2 (en) | 2003-03-31 | 2010-06-08 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Enhanced CTL epitope-containing HIV-1 reverse transcriptase polypeptides |
| WO2006091798A2 (en) * | 2005-02-22 | 2006-08-31 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Vaccines and methods for prevention and treatment of drug-resistant hiv-1 and hepatitis b virus |
| JP5668049B2 (en) * | 2009-03-24 | 2015-02-12 | ノバルティス アーゲー | Combination of meningococcal factor H binding protein and pneumococcal saccharide conjugate |
| AU2010227219B2 (en) * | 2009-03-24 | 2014-02-27 | Glaxosmithkline Biologicals S.A. | Adjuvanting meningococcal factor H binding protein |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7101294A (en) * | 1993-06-07 | 1995-01-03 | Endocon, Inc. | Implant stimulated cellular immunity |
| AU7465696A (en) * | 1995-10-20 | 1997-05-07 | Duke University | Synthetic vaccine for protection against human immunodeficiency virus infection |
| EP0942987B1 (en) * | 1996-11-26 | 2009-08-19 | Bio Merieux | Viral material and nucleotide fragments associated with multiple sclerosis, for diagnostic, prophylactic and therapeutic purposes |
-
1998
- 1998-04-03 DE DE19814925A patent/DE19814925C2/en not_active Expired - Fee Related
-
1999
- 1999-04-01 DE DE59914027T patent/DE59914027D1/en not_active Expired - Fee Related
- 1999-04-01 AT AT99919176T patent/ATE346935T1/en not_active IP Right Cessation
- 1999-04-01 BR BR9909389-8A patent/BR9909389A/en not_active IP Right Cessation
- 1999-04-01 AU AU37042/99A patent/AU3704299A/en not_active Abandoned
- 1999-04-01 CA CA2325345A patent/CA2325345C/en not_active Expired - Fee Related
- 1999-04-01 JP JP2000542462A patent/JP2002510496A/en active Pending
- 1999-04-01 KR KR1020007010972A patent/KR20010042400A/en not_active Application Discontinuation
- 1999-04-01 EP EP99919176A patent/EP1068331B1/en not_active Expired - Lifetime
- 1999-04-01 WO PCT/EP1999/002249 patent/WO1999051750A1/en active Search and Examination
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7619058B2 (en) | 2004-01-20 | 2009-11-17 | Aichi Prefecture | Epitope/peptide recognized by HLA-A2402-restricted Ep-CAM-specific CTL and use of the same |
| US7846651B2 (en) | 2004-01-20 | 2010-12-07 | Aichi Prefecture | Epitope/peptide recognized by HLA-A2402-restricted Ep-CAM-specific CTL and use of the same |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999051750A1 (en) | 1999-10-14 |
| CA2325345C (en) | 2010-06-29 |
| KR20010042400A (en) | 2001-05-25 |
| DE19814925A1 (en) | 1999-10-07 |
| DE59914027D1 (en) | 2007-01-11 |
| EP1068331B1 (en) | 2006-11-29 |
| AU3704299A (en) | 1999-10-25 |
| EP1068331A1 (en) | 2001-01-17 |
| JP2002510496A (en) | 2002-04-09 |
| ATE346935T1 (en) | 2006-12-15 |
| DE19814925C2 (en) | 2000-10-05 |
| BR9909389A (en) | 2000-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7569228B2 (en) | Fusion proteins of non-attenuated HIV regulatory/accessory proteins | |
| JP3587538B2 (en) | Synthetic polypeptides as inhibitors of HIV-1 | |
| BR9814725A (en) | "hiv-1 tat protein or derivatives thereof for prophylactic and therapeutic vaccination" | |
| RU2009106089A (en) | COMPOSITIONS CONTAINING A HUMAN ENDOGENOUS RETROVIRUS POLYPEPTIDE AND METHODS OF APPLICATION | |
| WO2014205579A4 (en) | Modified matrix proteins of vesicular stomatitis virus | |
| Otten et al. | Induction of broad and potent anti-human immunodeficiency virus immune responses in rhesus macaques by priming with a DNA vaccine and boosting with protein-adsorbed polylactide coglycolide microparticles | |
| CA2325345A1 (en) | Medicaments for inducing cytotoxic t-cells | |
| JP2004538334A (en) | Drugs used in the treatment of HIV infection and their components and uses | |
| Ansari et al. | Use of recombinant cytokines for optimized induction of antiviral immunity against SIV in the nonhuman primate model of human AIDS | |
| US20030228327A1 (en) | DNA-based plasmid formulations and vaccines and prophylactics containing the same | |
| GB0325011D0 (en) | HIV pharmaccines | |
| US20040058861A1 (en) | Use of lipopeptides in immunotherapy of HIV+ individuals | |
| O'Hagan et al. | Gillis Otten, Mary Schaefer, Catherine Greer, Maria |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20170403 |